Published in Pharmacol Ther on August 10, 2010
PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc Chem Res (2011) 1.30
Informatics and standards for nanomedicine technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.19
Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev (2012) 0.97
Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS One (2013) 0.96
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev (2011) 0.93
Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett (2012) 0.90
Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy. J Cancer Res Clin Oncol (2016) 0.86
The nanomedicine revolution: part 2: current and future clinical applications. P T (2012) 0.85
Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84
The nanomedicine revolution: part 1: emerging concepts. P T (2012) 0.83
Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond) (2013) 0.82
Folic acid targeted Mn:ZnS quantum dots for theranostic applications of cancer cell imaging and therapy. Int J Nanomedicine (2016) 0.81
Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine (2012) 0.81
Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. Cancers (Basel) (2011) 0.81
Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. Int J Nanomedicine (2015) 0.78
Anti-CEA loaded maghemite nanoparticles as a theragnostic device for colorectal cancer. Int J Nanomedicine (2012) 0.77
Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control. Int J Nanomedicine (2015) 0.77
Deep vein thrombosis: current status and nanotechnology advances. Biotechnol Adv (2012) 0.77
The nanomedicine revolution: part 3: regulatory and safety challenges. P T (2012) 0.77
Enhanced Bioactivity of α-Tocopheryl Succinate Based Block Copolymer Nanoparticles by Reduced Hydrophobicity. Macromol Biosci (2016) 0.76
Developments in the use of nanocapsules in oncology. Braz J Med Biol Res (2013) 0.76
Graphene-based platforms for cancer therapeutics. Ther Deliv (2016) 0.76
A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol (2016) 0.75
Synthesis of three-arm block copolymer poly(lactic-co-glycolic acid)-poly(ethylene glycol) with oxalyl chloride and its application in hydrophobic drug delivery. Int J Nanomedicine (2016) 0.75
Nanotechnology applications in hematological malignancies (Review). Oncol Rep (2015) 0.75
Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials (Basel) (2015) 0.75
Neuroantibody biomarkers: links and challenges in environmental neurodegeneration and autoimmunity. Autoimmune Dis (2014) 0.75
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
Lactate dehydrogenase as a biomarker for early renal damage in patients with sickle cell disease. Saudi J Kidney Dis Transpl (2015) 1.96
Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab (2009) 1.56
Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr (2012) 1.44
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol (2009) 1.43
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res (2009) 1.40
Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res (2004) 1.28
Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem (2011) 1.28
Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood (2003) 1.27
Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res (2006) 1.25
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine (2009) 1.25
Emerging nanopharmaceuticals. Nanomedicine (2008) 1.21
Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost (2003) 1.21
Metformin and neoplasia: implications and indications. Pharmacol Ther (2011) 1.20
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost (2007) 1.18
The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost (2007) 1.17
Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules (2009) 1.12
Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol (2011) 1.12
High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res (2012) 1.12
Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology (2009) 1.08
Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res (2003) 1.07
Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis. FEBS Lett (2007) 1.07
Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop (2011) 1.05
PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis (2008) 1.04
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol (2013) 1.03
Thyroid hormone and angiogenesis. Vascul Pharmacol (2009) 1.00
Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol (2009) 1.00
Current status and future directions in the management of chronic hepatitis C. Virol J (2012) 0.99
The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs (2002) 0.97
Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem (2006) 0.96
Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One (2011) 0.96
Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle (2009) 0.96
Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci (2014) 0.96
Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. J Immunol (2004) 0.95
Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res (2010) 0.95
Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis (2013) 0.95
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol (2008) 0.94
Green tea modulates reserpine toxicity in animal models. J Toxicol Sci (2009) 0.93
Current primary open-angle glaucoma treatments and future directions. Clin Ophthalmol (2012) 0.93
Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy. Biochim Biophys Acta (2008) 0.92
Biosensors: the new wave in cancer diagnosis. Nanotechnol Sci Appl (2010) 0.92
The Effects of EPA+DHA and Aspirin on Inflammatory Cytokines and Angiogenesis Factors. World J Cardiovasc Dis (2011) 0.91
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther (2007) 0.91
Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS Neurol Disord Drug Targets (2009) 0.90
Identification and functions of the plasma membrane receptor for thyroid hormone analogues. Discov Med (2011) 0.90
Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis (2002) 0.89
Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids (2011) 0.89
Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol (2011) 0.89
Adjunctive input to the nuclear thyroid hormone receptor from the cell surface receptor for the hormone. Thyroid (2013) 0.88
Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol (2009) 0.88
Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid (2010) 0.88
Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease. Cardiol J (2011) 0.88
Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers (Basel) (2011) 0.87
Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res (2011) 0.86
Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53. Nutr Cancer (2005) 0.86
The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol (2009) 0.86
Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis (2008) 0.85
Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol (2008) 0.85
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Vasc Health Risk Manag (2010) 0.85
Small molecule hormone or hormone-like ligands of integrin αVβ3: implications for cancer cell behavior. Horm Cancer (2013) 0.84
The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res (2009) 0.83
Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int (2011) 0.83
Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement therapy. J Womens Health (Larchmt) (2005) 0.83
Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardiovasc Pharmacol (2002) 0.83
Nuclear monomeric integrin αv in cancer cells is a coactivator regulated by thyroid hormone. FASEB J (2013) 0.82
Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond) (2013) 0.82
Micro- and nanoparticle-based vaccines for hepatitis B. Adv Exp Med Biol (2007) 0.82
Evaluation of platelet antagonists in in vitro flow models of thrombosis. Methods Mol Med (2004) 0.82
The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle (2009) 0.82
Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm Cancer (2013) 0.82
Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells. Physiol Behav (2009) 0.82
Treatment options for diabetes: potential role of stem cells. Diabetes Res Clin Pract (2012) 0.82
Current status of nucleoside antivirals in chronic hepatitis B. Drugs Today (Barc) (2009) 0.81
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. Pharmgenomics Pers Med (2009) 0.81
Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis (2010) 0.81
Molecular basis for certain neuroprotective effects of thyroid hormone. Front Mol Neurosci (2011) 0.81
Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps. Discov Med (2012) 0.81
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent. Pharmgenomics Pers Med (2009) 0.81
The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans. Prostaglandins Leukot Essent Fatty Acids (2012) 0.81
Prevention strategies for antimicrobial resistance: a systematic review of the literature. Infect Drug Resist (2010) 0.81
Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorder. Drug Healthc Patient Saf (2009) 0.81
Potential role of naturally derived polyphenols and their nanotechnology delivery in cancer. Mol Biotechnol (2013) 0.80
Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol Biol (2010) 0.80
Fibrin and collagen differentially but synergistically regulate sprout angiogenesis of human dermal microvascular endothelial cells in 3-dimensional matrix. Int J Cell Biol (2013) 0.80
Cellular conditioning with trichostatin A enhances the anti-stress response through up-regulation of HDAC4 and down-regulation of the IGF/Akt pathway. Aging Cell (2008) 0.80
Inhibition property of green tea extract in relation to reserpine-induced ribosomal strips of rough endoplasmic reticulum (rER) of the rat kidney proximal tubule cells. J Toxicol Sci (2009) 0.80
The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med (2012) 0.80
Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activity. Carbohydr Res (2009) 0.80
Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences. Crit Rev Food Sci Nutr (2010) 0.79
Current therapies and new strategies for the management of Alzheimer's disease. Am J Alzheimers Dis Other Demen (2010) 0.79
Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis (2013) 0.79
The antiplatelet activity of camel urine. J Altern Complement Med (2011) 0.79
Heparin-cellulose-charcoal composites for drug detoxification prepared using room temperature ionic liquids. Chem Commun (Camb) (2008) 0.79
Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine (2008) 0.79
Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. Adv Urol (2009) 0.79
Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer. Pharm Res (2015) 0.79
Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications. Curr Opin Investig Drugs (2010) 0.78
The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol (2008) 0.78
Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag (2008) 0.78
Thyroid hormone-induced angiogenesis. Curr Cardiol Rev (2009) 0.78